Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Health and Life Sciences at the Edge: Privacy Frameworks in Health and Life Sciences

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

The American Journal of Medicine noted that healthcare organizations, or HCOs, require a framework that preserves privacy and supports the kind of data collaboration that will make tomorrow’s scientific and clinical advances possible while still supporting improved patient outcomes and experiences. Establishing this framework is challenging. Can AI solutions meet those privacy requirements for healthcare and life science applications? This is the question host Hilary Kennedy posed to BeeKeeperAI’s CEO Michael Blum, MD and Intel’s Health and Life Sciences General Manager, Chris Gough.

“Even large health organizations do not have the diversity, quality, or amount of data required to create high-quality, generalizable AI,” said Blum. “The solution is a federated framework that allows each data steward to ensure the privacy of their data by keeping it in their protected cloud, while validating and training AI across all of those stewards.”

Gough agreed, saying, “If you can reduce the friction to accessing large, diverse, high-quality data sets – and use those data sets as part of the AI training step – then the algorithms that result will be more accurate for multiple populations.”

“Healthcare AI is projected to be a $46 billion dollar market. When you turn that into human impact, there’s a tremendous opportunity to improve the quality of care and reduce the cost of care,” said Blum. “But the challenge we see over-and-over again is that the algorithms don’t generalize across populations. Their accuracy and performance fall off dramatically. We have to get rapid access to much broader and much more diverse data sets.”

“We really have a supply and demand problem in healthcare,” Gough added. “AI will help the industry better target the scarce resources it has, allowing organizations to be less reactive and more proactive and predictive.”

To learn more about Michael Blum, MD, and Chris Gough:

Connect with them on LinkedIn

Visit https://www.beekeeperai.com/

Read the “Privacy-Preserving Data-Collaboration Methods that Accelerate Healthcare Innovation” white paper: https://www.intel.com/content/www/us/en/healthcare-it/resources/confidential-computing-whitepaper.html

Subscribe to this channel on Apple Podcasts, Spotify, or Google Podcasts to hear more from the Intel Internet of Things Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus’ $450M Alkeus deal puts phase 3 retina programs on the same integration plan

Tarsus has made a $450 million deal with Alkeus to acquire two assets, including a phase 3 oral Stargardt program and a post-injection antiseptic. The focus now moves to clinical trial operations, chemistry manufacturing and controls, and plans for specialty distribution. These acquisitions aim to expand Tarsus' retina programs.

  • 01Tarsus acquired a phase 3 oral Stargardt asset and a post-injection antiseptic for $450 million.
  • 02The acquisitions focus on enhancing clinical trial operations and chemistry manufacturing controls.
  • 03Plans for future specialty distribution of the acquired assets are in place.

Aug 29, 2026

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

FDA’s Oct. 19 AI docket forces medtech teams to write tests, not slide decks

The FDA has released a generative AI discussion paper proposing a shift towards competency-style evaluation and increased postmarket monitoring in the healthcare industry. This move may lead vendors and hospital buyers to prioritize developing robust testing protocols for AI applications. The focus is on ensuring reliable and safe AI implementation in medical technologies.

  • 01The FDA's discussion paper suggests implementing competency-style evaluation for AI in healthcare.
  • 02There is an emphasis on increased postmarket monitoring for AI applications in the medical field.
  • 03Vendors and hospital buyers are encouraged to focus on developing testing protocols rather than presentations.

Aug 29, 2026

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 brings smart glasses and AI into the purchasing cycle

SILMO Paris 2026 is focusing on integrating smart glasses and AI into the purchasing processes for optical retailers and labs. The event is anticipated to attract around 34,000 visitors and feature 950 exhibitors, indicating significant interest in AI imaging workflows and smart-glass innovations. The agenda highlights a future direction towards advanced technology in optical retail and laboratory settings.

  • 01SILMO Paris 2026 will host nearly 34,000 visitors and 950 exhibitors.
  • 02The event focuses on AI imaging workflows and smart-glass innovations for optical retailers and labs.
  • 03Significant interest is shown in integrating advanced technology within optical retail processes.

Aug 29, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512